Localization of PDGF-B protein in macrophages in all phases of atherogenesis

Coronary atherosclerosis: current therapeutic approaches and future trends

Invasive cardiovascular procedures, such as percutaneous translumenal coronary angioplasty (PTCA) and aorto-coronary bypass surgery (ACBS), that are currently employed in treating the coronary stenosis or occlusion caused by atherosclerosis represent a major therapeutic advance for managing coronary heart disease (CHD). However, the cellular proliferative response and associated intimal hyperplasia that can follow the damage to blood vessels that occurs with these procedures leads to late complications which cannot be effectively controlled by presently available drugs. Hence, a new approach is required for managing these complications, termed "restenosis" (in the case of PTCA) or "stenosis" (in the case of ACBS). Existing drug therapy is reviewed and some new approaches to this problem are provided herein. Further studies of growth factors and other substances that influence the cellular proliferative response that follows injury to the blood vessel wall could lead to the development of effective therapy. Inhibition of intimal hyperplasia and/or acceleration of endothelial cell re-growth provide a basis for such new approaches. Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), as well as endothelium-derived relaxing factor(s) (EDRF) and calcitonin gene-related peptide (CGRP) are among the substances discussed. Modification of certain currently available drugs (e.g. Ca(2+)-antagonists) could also be of value in meeting this therapeutic demand.

Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis

Oxidized low density lipoprotein (LDL) may play an important role in the pathogenesis of atherosclerosis. Recent evidence strongly suggests that oxidized LDL is present in atherosclerotic lesions in vivo: 1) LDL isolated from human and rabbit lesions (but not from normal intima) resembles oxidized LDL in its physical, chemical and immunological properties; 2) Oxidized LDL and/or oxidation specific lipid-protein adducts can be demonstrated in human and rabbit lesions by immunocytochemical techniques; 3) Human and rabbit serum contains autoantibodies against oxidized LDL and oxidation specific lipid-protein adducts; 4) atherosclerotic lesions contain IgG that recognizes oxidized LDL and 5) antioxidant therapy slows the development of atherosclerotic lesions in rabbits. Atherosclerosis in human and rabbit arteries may be linked to macrophage-induced oxidative modification of LDL mediated by 15-lipoxygenase which leads to an enhanced uptake of LDL in macrophages by way of the scavenger receptor(s). The identification of LDL oxidation as one of the key events in the early pathogenesis of atherosclerosis offers an interesting possibility to reduce atherosclerosis by antioxidants, enzyme inhibitors and other compounds that protect LDL against oxidative damage and/or reduce the subsequent harmful effects of oxidized LDL on various cellular functions.

Comparative studies on the platelet-derived growth factor-A and -B gene expression in human monocytes

1. Platelet-derived growth factor (PDGF)-A and -B gene expression was studied in human monocytes. 2. Resting monocytes constitutively transcribed both PDGF-A and -B genes. When monocytes were stimulated by lipopolysaccharide (LPS), transcription rates of both genes were increased in a similar fashion. 3. Consistent with the transcription rates, resting monocytes constitutively expressed both PDGF-A and -B mRNAs. After LPS stimulation, the PDGF-A mRNA level increased gradually, while the PDGF-B mRNA level increased markedly and then decreased rapidly. 4. Reverse transcription-polymerase chain reaction showed that resting monocytes expressed only short PDGF-A mRNA species (representing exons I-V + VII), but LPS-stimulated monocytes expressed long PDGF-A mRNA species (representing exons I-VII) as well. Both resting and LPS-stimulated monocytes expressed only one PDGF-B mRNA species (representing exons I-VII). 5. Together these observations indicate that expression of PDGF-A and -B genes is differentially regulated at the levels of mRNA splicing and mRNA accumulation in monocytes, while transcription of both genes seems to be similarly controlled.

TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop

Transforming growth factor-beta (TGF-beta) acts as a growth inhibitor, yet it can stimulate proliferation; 1-2 fg/cell of TGF-beta 1 elicits maximal proliferation of dense and sparse cultured smooth muscle cells (SMCs), whereas higher amounts are less stimulatory. This bimodal response is not limited to SMCs, as TGF-beta induces a similar response in human fibroblasts and chondrocytes. The amount of TGF-beta 1 per cell that induces maximal proliferation is identical for dense and sparse SMCs. At low concentrations of TGF-beta, there is a 10-12 hr delay in DNA synthesis compared with that elicited by PDGF. PDGF-AA is detected in the culture medium at 24 hr, and anti-PDGF IgG blocks DNA synthesis. At higher concentrations, TGF-beta 1 decreases transcripts and expression of PDGF receptor alpha subunits. Hence, TGF-beta induces proliferation of connective tissue cells at low concentrations by stimulating autocrine PDGF-AA secretion, which at higher concentrations of TGF-beta, is decreased by down-regulation of PDGF receptor alpha subunits and perhaps by direct growth inhibition.

Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging

Diabetes and aging are commonly accompanied by arterio- and atherosclerosis. Infiltration of the arterial subendothelial intima by macrophages/monocytes is an important early event preceding the development of atheromatous lesions; these macrophages are known to produce mitogenic factors in early atherosclerotic lesions. It has been previously shown that, over time, vascular matrix accumulates proteins nonenzymatically modified by advanced glycosylation end products (AGEs). In view of the fact that macrophages/monocytes have AGE-specific receptors associated with the expression of several growth factors, we investigated the possibility that AGEs mediate initial monocyte-vessel wall interactions that occur before overt formation of vascular lesions. This study demonstrates that (i) in vitro- and in vivo-formed AGEs are chemotactic for human blood monocytes, (ii) sub-endothelial AGEs can selectively induce monocyte migration across an intact endothelial cell monolayer, and (iii) subsequent monocyte interaction with AGE-containing matrix results in the expression of platelet-derived growth factor. These results support the existing hypothesis that in vivo-forming glucose-derived protein adducts can act as signals for the normal turnover of senescent tissue protein by means of the AGE-specific receptor system. Time-dependent glucose-induced deposition of AGEs on matrix proteins may promote monocyte infiltration into the subendothelium. Subsequent AGE-triggered macrophage activation and consequent elaboration of proliferative factors may normally coordinate remodeling but may also lead to the diverse pathogenic changes typical of arterio- and atherosclerosis in diabetic or aging populations.